Breaking News
January 17, 2018 - Lactation May Lower T2D Risk in Younger Women
January 17, 2018 - New Atopic Dermatitis Yardstick provides practical guidance and management insights
January 17, 2018 - New biodegradable pressure sensor could help monitor serious health conditions
January 17, 2018 - HSS orders Sectra’s 3D pre-operative planning solution for improving patient outcomes
January 17, 2018 - Study identifies six new genes regions associated with diabetes
January 17, 2018 - Women do not receive timely diagnosis for heart disease
January 17, 2018 - AbbVie’s Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
January 17, 2018 - Should President Trump’s Physical Include a Cognitive Screen?
January 17, 2018 - Could gene therapy someday eliminate HIV?
January 17, 2018 - Researchers identify new anti-inflammatory drug target
January 17, 2018 - Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
January 17, 2018 - Trunk Imaging Tied to Higher Nephrectomy Risk
January 17, 2018 - Campaigners incensed at failings in Africa AIDS war
January 17, 2018 - Research opens door to development of new treatment for type 2 diabetes
January 17, 2018 - Bariatric surgery extends lifespan in obese patients, shows study
January 17, 2018 - Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
January 17, 2018 - Ewww Moments in the ER: That’s Improbable!
January 17, 2018 - Methods from optogenetics, machine learning should help improve treatment options for stroke patients
January 17, 2018 - Booze may help or harm the heart, but income matters
January 17, 2018 - Three-dimensional organization of genome plays key role in gene expression, cell fate
January 17, 2018 - Scientists identify six new gene regions that may help treat type 1 diabetes
January 17, 2018 - Top nutrients needed to boost mood and energy levels on Blue Monday
January 17, 2018 - Scientists develop unique technique to map elasticity of cell components
January 17, 2018 - Obesity surgery reduces the risk of death by half finds new study
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - Men who lack HSD17B4 gene may be more susceptible to treatment-resistant prostate cancer
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
Including Drug to Same old Care Would possibly Extend Lymphoma Survival

Including Drug to Same old Care Would possibly Extend Lymphoma Survival

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Sept. 27, 2017 (HealthDay Information) — Lengthy-term remedy with the drug rituximab (Rituxan) might lengthen the lives of a few sufferers with an extraordinary type of blood most cancers, a brand new medical trial unearths.

The illness, referred to as mantle-cell lymphoma, is usually incurable. However quite a lot of therapies can extend other people’s lives. Some sufferers, as an example, are in a position to go through chemotherapy to wipe out the most cancers cells, adopted by way of a stem cellular transplant — to revive customary blood cells.

However whilst that means will also be efficient for some time, maximum sufferers see the most cancers come again.

So the brand new trial, funded by way of Rituxan maker Roche, checked out whether or not an extra step may assist: Having sufferers take Rituxan for 3 years following their stem cellular transplant.

Total, researchers discovered, the strategy did enhance sufferers’ outlook. After 4 years, 83 p.c of rituximab sufferers had been nonetheless alive and progression-free — as opposed to 64 p.c of sufferers who had same old remedy on my own.

Professionals mentioned the findings must have a direct have an effect on on sufferers’ remedy.

“This must be regarded as a brand new same old of care,” mentioned Dr. Anas Younes, leader of the lymphoma carrier at Memorial Sloan Kettering Most cancers Middle, in New York Town.

Alternatively, there are considerations with the long-term use of rituximab, consistent with Younes, who wasn’t concerned within the learn about.

The drug suppresses the immune device, so infections are at all times a possibility, he famous.

“However,” Younes added, “the advantages appear to outweigh the dangers.”

Dr. Steven Le Gouill, of Nantes Scientific College, in France, led the learn about.

He agreed that “rituximab repairs” — the usage of it long-term, after a stem cellular transplant — must turn into a brand new same old.

“The achieve in the case of total survival must inspire hematologists to prescribe rituximab repairs for transplanted sufferers,” Le Gouill mentioned.

Mantle-cell lymphoma is one in every of about 70 subtypes of non-Hodgkin lymphoma, consistent with the Leukemia & Lymphoma Society. In the USA, about four,200 individuals are identified with the illness every 12 months — maximum regularly, older males.

Medical doctors have lengthy used rituximab to regard sure cancers, together with mantle-cell lymphoma. The drug is a lab-engineered antibody that latches onto a protein on white blood cells (lymphocytes) known as B cells; the ones are the cells which are affected in mantle-cell lymphoma.

Because it stands, rituximab is used in conjunction with high-dose chemotherapy medicine to wipe out the cancerous B cells. Some sufferers then go through an “autologous” stem cellular transplant. That implies they’ve a few of their very own blood-forming stem cells got rid of prior to their drug routine; in a while, the stem cells are infused again into the frame, to revive new, wholesome blood cells.

Some sufferers — together with those that are older and frail — can not have a transplant.

However different analysis has proven that rituximab repairs, given after same old drug remedy to power out the most cancers, can lengthen the ones sufferers’ lives, Younes mentioned.

The brand new findings display the similar is correct for sufferers who do have a transplant.

The trial concerned 299 sufferers who had been more youthful than 66 once they had been identified with mantle-cell lymphoma. All underwent same old drug remedy, with rituximab and chemotherapy. Maximum — 86 p.c — spoke back neatly sufficient to go through a stem cellular transplant.

Part of the sufferers had been then randomly assigned to a few years of rituximab repairs remedy, receiving IV infusions of the drug each two months. The remaining had been adopted up with same old care.

After 4 years, 89 p.c of rituximab sufferers had been nonetheless alive, in comparison with 80 p.c within the comparability staff, the investigators discovered.

The rituximab sufferers had been additionally much more likely to stay freed from a most cancers relapse, or severe negative effects — together with critical infections and allergies: That was once true of 79 p.c of rituximab sufferers, as opposed to 61 p.c of sufferers on same old care.

In line with Le Gouill, “Rituximab repairs after stem cellular transplant is one new weapon within the arsenal to struggle towards mantle-cell lymphoma.”

He famous that different therapies were lately authorized — oral medicine that focus on abnormalities at the most cancers cells — whilst nonetheless others are in construction.

Like different antibody medicine, rituximab is pricey — operating 1000’s of greenbacks per thirty days after medical institution fees, consistent with a printed record. Repayment “might be a topic in some nations,” Le Gouill famous.

However, he added, the associated fee needs to be weighed towards the truth that the drug lengthens sufferers’ lives and has “low toxicity.”

Younes mentioned that the “vital message” from the findings is that sufferers’ survival time is constant to enhance.

The learn about findings had been printed Sept. 28 within the New England Magazine of Medication.

SOURCES: Steven Le Gouill, M.D., Ph.D., hematology carrier, Nantes Scientific College, Nantes, France; Anas Younes, M.D., leader, lymphoma carrier, Memorial Sloan Kettering Most cancers Middle, New York Town; Sept. 28, 2017, New England Magazine of Medication

Information tales are written and equipped by way of HealthDay and don’t replicate federal coverage, the perspectives of MedlinePlus, the Nationwide Library of Medication, the Nationwide Institutes of Well being, or the U.S. Division of Well being and Human Products and services.

Tagged with:

About author

Related Articles